AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 161 min read$OSCR

OSCR: Raised 2026–2029 guidance, targeting 20%+ revenue CAGR, 5–7% margins, and $4+ EPS, driven by ACA and AI

Oscar Health (OSCR) raised its 2026–2029 guidance, targeting 20%+ revenue CAGR, 5–7% margins, and $4+ EPS, driven by ACA expansion and AI. The company aims to lead the individual health market through AI efficiency and product innovation, with the Lucie Health Marketplace as a long-term opportunity, though not critical to targets.

Original reporting
tradingview.com
Published Sep 16, 2026, 6:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OSCR: Raised 2026–2029 guidance, targeting 20%+ revenue CAGR, 5–7% margins, and $4+ EPS, driven by ACA and AI — source image
Source · tradingview.com
Decision brief

The 30-second read

$OSCRBullishMed
01

Why it matters

The raised guidance signals stronger financial health and may attract new capital, while the AI strategy could differentiate the company in a competitive market.

02

Market read

Guidance uplift is a material catalyst for OSCR and may influence related health‑tech stocks.

03

What to watch

The guidance does not depend on the success of the Lucie Health Marketplace, which may limit upside if the platform underperforms.

Relevance 7/10Novelty 8/10Timing: post Investor Day 2026

Background

Oscar Health held its Investor Day, presenting a strategic roadmap focused on AI‑driven efficiency and the Lucie Health Marketplace.

Company-level read

Ticker impact

$OSCRBullishHigh confidence
Context

Oscar Health raised its 2026‑2029 guidance, targeting $4+ EPS and 5‑7% margins, indicating stronger future profitability.

Expected impact

Potential upside of 5‑10% over the next weeks as investors reprice earnings expectations.

Evidence & confidence

Guidance is a primary disclosure with concrete numbers; market typically reacts positively to earnings outlook upgrades.

Market effects

Sector

Higher guidance may lift other health‑tech and ACA‑related insurers as investors anticipate sector tailwinds.

Regional

U.S. health‑insurance market could see modest buying pressure.

Global

Limited to U.S. markets; no direct global impact.

Counterpoint

What could challenge this read

If the guidance relies heavily on ACA expansion, any policy reversal could undermine the upside.

Key entities

  • Company
    Oscar Health, Inc.

    U.S. health‑insurance provider (ticker OSCR).

  • Product
    Lucie Health Marketplace

    AI‑enabled health‑service platform highlighted in the guidance.

Read at source← All news

Related articles

SEP 16
$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

tipranks.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

scanx.trade2 min
SEP 5
$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.

stocktwits.com2 min